Abrdn Life Sciences Investors (HQL) Fair Value 2026

HQL · Asset Management ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.9 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-10-07, Abrdn Life Sciences Investors (HQL) trades at $17.56, versus a $92.82 median fair value across its 2 active models — 428.6% above the current price. QOC: 4.9/10. Value Trap Risk: 0/100 (SAFE). 2/13 models active.

Key Facts

Ticker
HQL
Price
$17.56
Quality Score
4.9/10
Value Trap Risk
0/100
Models Active
2/13
Last Updated
Strength: Regime Cross-Sectional suggests +429.8% upside with 12% confidence
Risk: Below-average Quality Score of 4.9/10 signals weak fundamentals

Is Abrdn Life Sciences Investors (HQL) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Abrdn Life Sciences Investors (HQL) appears undervalued as of : the median of 2 independent fair value estimates is $92.82, 428.6% above the current price of $17.56. Estimates range from $92.60 to $93.04. HQL scores 4.9/10 on fundamental quality and 0/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. HQL’s +428.6% gap is wider than that market norm, and the Asset Management sector median is +3.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Abrdn Life Sciences Investors Stock in 2026? →

What Fair Value Does Each Model Give HQL?

2 Intrinsic Value Models vs. Current Price ($17.56)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $92.60 +427.3%
Relative · Low Conviction
 $93.04 +429.8%

All Models Active

All 2 models are displayed above.

What Is Abrdn Life Sciences Investors (HQL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Abrdn Life Sciences Investors's intrinsic value is estimated at a median fair value of $92.82. At a current market price of $17.56, 2 of 2 active valuation models identify upside potential, projecting a median implied return of +428.6%.

What Do the Models Say About HQL?

2 of 13 models are currently active for HQL. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for HQL is $92.82 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does HQL Rank in Asset Management?

Among 187 Asset Management stocks, HQL ranks #113 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.

See all Most Undervalued Asset Management Stocks →

Abrdn Life Sciences Investors operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is HQL a Value Trap?

CirclFi's Value Trap algorithm assigns HQL a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Abrdn Life Sciences Investors. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Abrdn Life Sciences Investors's fundamental quality profile registers 4.9/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+2.5% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HQL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HQL's 2 active models, average confidence is 13%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Abrdn Life Sciences Investors Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Asset Management Stocks Should You Also Analyze?

11 related Asset Management stocks with 13-model coverage

RVTRoyce Small-Cap Trust, Inc.QOC 4.9PPTFranklin Premier Income TrustQOC 4.9JHSJohn Hancock Income Securities TrustQOC 5.0PSPershing Square Inc.QOC 4.9BGRBlackRock Energy and Resources TrustQOC 5.0BMEBlackRock Health Sciences TrustQOC 4.9OCCIOFS Credit Company, Inc.QOC 3.8VCTRVictory Capital Holdings, Inc.QOC 8.0SARSaratoga Investment Corp.QOC 6.2HLNEHamilton Lane IncorporatedQOC 9.3AMPAmeriprise Financial, Inc.QOC 9.3

Read investment analysis: RVT · PPT · JHS · PS · BGR · BME · OCCI · VCTR · SAR · HLNE · AMP

Which Other Stocks Have a Similar Quality Score to HQL?

6 companies across all industries closest to HQL’s Quality of Company score of 4.9/10.

MGRXMangoceuticals, Inc.QOC 4.9VTVTvTv Therapeutics Inc.QOC 4.9BIAFbioAffinity Technologies, Inc.QOC 4.9SUICSUIC Worldwide Holdings Ltd.QOC 4.9SVIASilvia, Inc.QOC 4.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MGRX · VTVT · BIAF · SUIC · SVIA · NVDA

Where Does HQL Sit in CirclFi's Asset Management Rankings?

HQL is ranked against every other Asset Management stock CirclFi covers in each of these screens.

See all Asset Management stocks ranked →

What Else Do Investors Ask About Abrdn Life Sciences Investors’s Valuation?

What is Abrdn Life Sciences Investors's intrinsic value in 2026?

CirclFi puts Abrdn Life Sciences Investors (HQL)'s intrinsic value at $92.82 — the median of 2 independent model estimates as of 2026-10-07, ranging from $92.60 to $93.04. The Quality of Company score is 4.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HQL overvalued or undervalued right now?

At $17.56, 2 of 2 active models suggest HQL may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $92.82, 428.6% above the current price of $17.56 — a consensus view that HQL is undervalued. The assessment depends on which methodology best fits Abrdn Life Sciences Investors's business model in Asset Management.

What does a Quality of Company score of 4.9 mean for HQL?

Abrdn Life Sciences Investors's QOC of 4.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HQL?

CirclFi analyzes HQL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is HQL a value trap in 2026?

Abrdn Life Sciences Investors's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Abrdn Life Sciences Investors (HQL) has a median fair value of $92.82 — 428.6% above the current price of $17.56 — as of 2026-10-07.” Source: circlfi.com/stock/HQL/ · Methodology
Primary sources for this HQL valuation
  • Financial statements: Abrdn Life Sciences Investors 10-K and 10-Q filings on SEC EDGAR (CIK 0000884121) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HQL as of ; valuations recomputed .